Vanda Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDAGet Free Report) was the target of some unusual options trading on Wednesday. Stock traders purchased 7,001 call options on the company. This is an increase of approximately 1,878% compared to the average volume of 354 call options.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VNDA. GSA Capital Partners LLP grew its holdings in Vanda Pharmaceuticals by 39.8% in the fourth quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 161,737 shares during the last quarter. Public Employees Retirement System of Ohio grew its stake in Vanda Pharmaceuticals by 61.2% in the 4th quarter. Public Employees Retirement System of Ohio now owns 121,948 shares of the biopharmaceutical company’s stock valued at $515,000 after acquiring an additional 46,300 shares during the last quarter. Barclays PLC increased its holdings in Vanda Pharmaceuticals by 33.7% during the 4th quarter. Barclays PLC now owns 171,638 shares of the biopharmaceutical company’s stock valued at $725,000 after acquiring an additional 43,308 shares in the last quarter. Wolverine Trading LLC acquired a new position in Vanda Pharmaceuticals during the fourth quarter worth about $47,000. Finally, Nantahala Capital Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 1.3% in the fourth quarter. Nantahala Capital Management LLC now owns 1,013,251 shares of the biopharmaceutical company’s stock valued at $4,276,000 after purchasing an additional 13,251 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on VNDA. StockNews.com raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 29th. TheStreet downgraded shares of Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Thursday, February 8th.

Read Our Latest Stock Report on VNDA

Vanda Pharmaceuticals Stock Up 39.6 %

Shares of Vanda Pharmaceuticals stock traded up $1.55 during trading on Wednesday, reaching $5.46. The company’s stock had a trading volume of 33,961,896 shares, compared to its average volume of 1,478,092. The business has a 50 day moving average price of $4.02 and a 200-day moving average price of $4.05. The company has a market capitalization of $314.17 million, a P/E ratio of 103.82 and a beta of 0.76. Vanda Pharmaceuticals has a 12-month low of $3.30 and a 12-month high of $7.00.

Vanda Pharmaceuticals (NASDAQ:VNDAGet Free Report) last issued its earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. The company had revenue of $45.27 million for the quarter, compared to analyst estimates of $37.00 million. Research analysts predict that Vanda Pharmaceuticals will post 0.01 EPS for the current fiscal year.

About Vanda Pharmaceuticals

(Get Free Report)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Further Reading

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.